MS and Demyelinating Disorders

Tiziana Life Sciences presents the design a phase 2a trial of nasal foralumab for treating nonactive secondary progressive MS at ECTRIMS 2025.

Tolebrutinib shows promise in improving quality of life for patients with nonrelapsing secondary progressive multiple sclerosis, according to recent trial findings.

Ofatumumab shows promising efficacy in treating neuromyelitis optica spectrum disorder, significantly reducing relapse rates and improving patient outcomes.

A new trial evaluates PIPE-307, a drug targeting M1 receptors, aiming to promote remyelination in relapsing-remitting multiple sclerosis patients.

Tolebrutinib, a promising BTK inhibitor for nonrelapsing MS, faces a delayed FDA review, highlighting its potential in treating neuroinflammation.

The latest McDonald Diagnostic Criteria revisions integrate imaging, biomarkers, and laboratory testing to create a more accurate, globally applicable framework for earlier diagnosis in MS.

A groundbreaking study reveals the connection between GLP-1 hormones and brain inflammation in neuromyelitis optica spectrum disorder, suggesting new treatment avenues.

New research revealed that mesenchymal stem cells from patients with secondary progressive multiple sclerosis may increase proinflammatory T-cell activities compared with those from healthy controls.

Tamara Kaplan, MD, vice chair of education for the department of neurology at Mass General Brigham, shares insights on evolving neurology education, highlighting her framework for supporting clinician educators and the growing recognition of education as a career path.

The vice chair of neurology at West Virginia University reflected on receiving the AUPN Leadership Award, addressing challenges in academic neurology and the evolving responsibilities of vice chairs in advancing departmental goals.

Here's some of what is coming soon to NeurologyLive® this week.

A recent study reveals that personalized extended interval dosing of natalizumab significantly reduces JCV seroconversion risk in patients with MS.

Bio-Thera Solutions announced that its pivotal trial of BAT4406F, an anti-CD20 monoclonal antibody, for neuromyelitis optica spectrum disorder will close enrollment early after achieving statistically significant efficacy.

New findings from a randomized trial reported no difference in relapse rates or new T2 lesions between a personalized lifestyle app and a nonpersonalized version for multiple sclerosis.

Here's some of what is coming soon to NeurologyLive® this week.

The vice chair of education for the department of neurology at Mass General outlined her AUPN 2025 session on supporting clinician educators through recognition, career development, and institutional frameworks for advancement. [WATCH TIME: 4 minutes]

The neurologist at Maimonides Medical Center and SUNY Downstate shared how interactive simulations give neurology trainees the chance to practice skills, gain feedback, and move beyond passive learning. [WATCH TIME: 3 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

A newly reported case highlights acute retinal necrosis from varicella zoster virus in a patient with multiple sclerosis on dimethyl fumarate, underscoring the need to consider non–optic neuritis causes of vision loss.

Here's some of what is coming soon to NeurologyLive® this week.

Neurology News Network. for the week ending August 16, 2025. [WATCH TIME: 4 minutes]

A new study reveals rituximab outperforms cladribine in managing MRI disease activity in relapsing multiple sclerosis over 4.5 years.

At CMSC 2025, assistant professor of neurology at the University of California, San Francisco discussed progress on the integration of biomarkers into clinical practice for multiple sclerosis. [WATCH TIME: 4 minutes]

A new study reveals higher rates of postpartum depression in women with multiple sclerosis, emphasizing the need for early screening and management strategies.

New findings highlight the potential of sCD83 as a prognostic biomarker in NMOSD and MOGAD, supporting its role as both a therapeutic target and a marker of treatment response in these autoimmune diseases.